5,999 Shares in Charles River Laboratories International, Inc. $CRL Purchased by Quantitative Investment Management LLC

Quantitative Investment Management LLC acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL) in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,999 shares of the medical research company’s stock, valued at approximately $1,360,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Jones Financial Companies Lllp boosted its holdings in Charles River Laboratories International by 167.6% in the first quarter. Jones Financial Companies Lllp now owns 1,715 shares of the medical research company’s stock worth $253,000 after purchasing an additional 1,074 shares during the period. Empowered Funds LLC bought a new stake in Charles River Laboratories International during the first quarter valued at $418,000. American Century Companies Inc. raised its holdings in shares of Charles River Laboratories International by 41.9% during the second quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock worth $830,000 after purchasing an additional 1,616 shares during the period. Brown Advisory Inc. raised its holdings in shares of Charles River Laboratories International by 5.1% during the second quarter. Brown Advisory Inc. now owns 2,333 shares of the medical research company’s stock worth $354,000 after purchasing an additional 114 shares during the period. Finally, California Public Employees Retirement System lifted its position in shares of Charles River Laboratories International by 3.9% in the 2nd quarter. California Public Employees Retirement System now owns 84,605 shares of the medical research company’s stock worth $12,837,000 after buying an additional 3,198 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $289.02 on Tuesday. Charles River Laboratories International, Inc. has a 1 year low of $144.26 and a 1 year high of $303.30. The company has a market cap of $13.80 billion, a price-to-earnings ratio of -59.59, a price-to-earnings-growth ratio of 3.03 and a beta of 1.38. The company has a debt-to-equity ratio of 0.92, a quick ratio of 1.04 and a current ratio of 1.35. The firm has a fifty day moving average of $248.22 and a 200-day moving average of $198.15.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings data on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, topping analysts’ consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The company’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter last year, the company earned $3.12 EPS. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 11.33 earnings per share for the current year.

Wall Street Analyst Weigh In

CRL has been the subject of several research reports. Mizuho set a $264.00 price objective on shares of Charles River Laboratories International in a research report on Monday, August 10th. Barclays reiterated an “overweight” rating and set a $300.00 price objective on shares of Charles River Laboratories International in a research note on Wednesday, August 5th. BNP Paribas Exane set a $250.00 target price on Charles River Laboratories International in a research note on Wednesday, July 1st. Sanford C. Bernstein set a $250.00 target price on Charles River Laboratories International in a report on Wednesday, July 1st. Finally, CLSA cut Charles River Laboratories International from an “outperform” rating to a “hold” rating and set a $219.00 price target on the stock. in a research report on Monday, July 20th. Twelve research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $255.65.

Insider Transactions at Charles River Laboratories International

In other news, CAO Michael Gunnar Knell sold 6,645 shares of the business’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $260.38, for a total transaction of $1,730,225.10. Following the completion of the transaction, the chief accounting officer directly owned 11,852 shares in the company, valued at approximately $3,086,023.76. The trade was a 35.92% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director James C. Foster sold 75,000 shares of the stock in a transaction that occurred on Monday, June 29th. The stock was sold at an average price of $225.00, for a total value of $16,875,000.00. Following the completion of the transaction, the director directly owned 31,596 shares of the company’s stock, valued at $7,109,100. This trade represents a 70.36% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 165,990 shares of company stock worth $42,606,388 in the last quarter. 1.30% of the stock is currently owned by corporate insiders.

About Charles River Laboratories International

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.